Gilder Gagnon Howe & Co’s Intersect ENT, Inc XENT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-83,391	Closed	-$3.12M	–	303
2018 Q2	$3.12M	Buy	83,391 +16,834	+25%	+$661K	0.03%	194
2018 Q1	$2.62M	Buy	+66,557	New	+$2.43M	0.03%	200
2016 Q2	–	Sell	-949	Closed	-$18K	–	287
2016 Q1	$18K	Hold	949	–	–	﹤0.01%	230
2015 Q4	$21K	Sell	949 -49,173	-98%	-$972K	﹤0.01%	240
2015 Q3	$1.17M	Sell	50,122 -17,106	-25%	-$472K	0.02%	187
2015 Q2	$1.93M	Buy	67,228 +7,286	+12%	+$191K	0.03%	192
2015 Q1	$1.55M	Buy	59,942 +777	+1%	+$17.8K	0.02%	190
2014 Q4	$1.1M	Buy	59,165 +45,055	+319%	+$811K	0.02%	201
2014 Q3	$219K	Buy	+14,110	New	+$212K	﹤0.01%	248

Other funds holding XENT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's XENT Position: Q3 2018 in Review

Gilder Gagnon Howe & Co sold out of Intersect ENT, Inc (XENT) in Q3 2018, closing a stake of 83,391 shares — an estimated $3.12M sold.

Gilder Gagnon Howe & Co first reported a position in XENT in Q3 2014 and held it in 9 quarters. The position peaked at $3.12M in Q2 2018. 138 funds tracked by Wall St. Rank hold XENT as of Q3 2018.

Gilder Gagnon Howe & Co reported no remaining Intersect ENT, Inc position as of Q3 2018 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 83,391 Intersect ENT, Inc shares in Q3 2018, an estimated $3.12M.
Gilder Gagnon Howe & Co first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 9 quarters.
Gilder Gagnon Howe & Co's Intersect ENT, Inc position peaked at $3.12M in Q2 2018.
138 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2018.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2018, filed 30 Oct 2018.